Yao-Jun Yu1, Wei-Jian Sun1, Ming-Dong Lu1, Fei-Hai Wang1, Dan-Si Qi1, Yi Zhang1, Pi-Hong Li1, He Huang1, Tao You1, Zhi-Qiang Zheng1. 1. Yao-Jun Yu, Wei-Jian Sun, Ming-Dong Lu, Fei-Hai Wang, Dan-Si Qi, Yi Zhang, Pi-Hong Li, He Huang, Tao You, Zhi-Qiang Zheng, NO H09 Disease Dist., Department of General Surgery, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325003, Zhejiang Province, China.
Abstract
AIM: To investigate the clinical efficacy and toxic effects of neoadjuvant chemotherapy using docetaxel combined with oxaliplatin and fluorouracil for treating stage III/IV gastric cancer. METHODS: A total of 53 stage III/IV gastric cancer patients were enrolled into the study and treated with neoadjuvant chemotherapy. Two of the cases were excluded. The program was as follows: 75 mg/m(2) docetaxel and 85 mg/m(2) oxaliplatin on day 1 and 1500 mg/m(2) fluorouracil on days 1 to 3 for three weeks. RESULTS: The tumour changes, postoperative remission rate, changes in the symptoms and adverse reactions were observed. The overall clinical efficacy (complete remission + partial remission) of the neoadjuvant chemotherapy was 62.7%. R0 radical resection was performed on 60.8% of the patients, with a remission rate (pathological complete response + pathological subtotal response + pathological partial response) of 74.2%. The Karnofksy score improved in 42 cases. The toxicity reactions mostly included myelosuppression, followed by gastrointestinal mucosal lesions, nausea, vomiting and diarrhoea. CONCLUSION: Neoadjuvant chemotherapy consisting of docetaxel combined with oxaliplatin and fluorouracil is effective for stage III/IV gastric cancer. However, the treatment is associated with a high incidence of bone marrow suppression, which should be managed clinically.
AIM: To investigate the clinical efficacy and toxic effects of neoadjuvant chemotherapy using docetaxel combined with oxaliplatin and fluorouracil for treating stage III/IV gastric cancer. METHODS: A total of 53 stage III/IV gastric cancerpatients were enrolled into the study and treated with neoadjuvant chemotherapy. Two of the cases were excluded. The program was as follows: 75 mg/m(2) docetaxel and 85 mg/m(2) oxaliplatin on day 1 and 1500 mg/m(2) fluorouracil on days 1 to 3 for three weeks. RESULTS: The tumour changes, postoperative remission rate, changes in the symptoms and adverse reactions were observed. The overall clinical efficacy (complete remission + partial remission) of the neoadjuvant chemotherapy was 62.7%. R0 radical resection was performed on 60.8% of the patients, with a remission rate (pathological complete response + pathological subtotal response + pathological partial response) of 74.2%. The Karnofksy score improved in 42 cases. The toxicity reactions mostly included myelosuppression, followed by gastrointestinal mucosal lesions, nausea, vomiting and diarrhoea. CONCLUSION: Neoadjuvant chemotherapy consisting of docetaxel combined with oxaliplatin and fluorouracil is effective for stage III/IV gastric cancer. However, the treatment is associated with a high incidence of bone marrow suppression, which should be managed clinically.
Authors: Ulas Darda Bayraktar; Soley Bayraktar; Peter Hosein; Emerson Chen; Leonidas G Koniaris; Caio Max S Rocha-Lima; Alberto J Montero Journal: Med Oncol Date: 2011-10-28 Impact factor: 3.064
Authors: H H Hartgrink; C J H van de Velde; H Putter; I Songun; M E T Tesselaar; E Klein Kranenbarg; J E de Vries; J A Wils; J van der Bijl; J H J M van Krieken Journal: Eur J Surg Oncol Date: 2004-08 Impact factor: 4.424
Authors: Jaffer A Ajani; David J Bentrem; Stephen Besh; Thomas A D'Amico; Prajnan Das; Crystal Denlinger; Marwan G Fakih; Charles S Fuchs; Hans Gerdes; Robert E Glasgow; James A Hayman; Wayne L Hofstetter; David H Ilson; Rajesh N Keswani; Lawrence R Kleinberg; W Michael Korn; A Craig Lockhart; Kenneth Meredith; Mary F Mulcahy; Mark B Orringer; James A Posey; Aaron R Sasson; Walter J Scott; Vivian E Strong; Thomas K Varghese; Graham Warren; Mary Kay Washington; Christopher Willett; Cameron D Wright; Nicole R McMillian; Hema Sundar Journal: J Natl Compr Canc Netw Date: 2013-05-01 Impact factor: 11.908
Authors: R Molina; A Lamarca; B Martínez-Amores; A Gutiérrez; A Blázquez; A López; J Granell; M Álvarez-Mon Journal: Eur J Surg Oncol Date: 2013-06-05 Impact factor: 4.424